Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Milton

Showing results (151-160 of 182) with videos related to

Pageof 19
Sort By:
Transplantation and Cellular Therapy|May 18, 2025
Outcomes of Multiple Myeloma Patients With Prior Solid Tumors Undergoing Autologous TransplantationOren Pasvolsky, Curtis Marcoux, Denái R Milton, et al.
Transplantation and Cellular Therapy|August 2, 2025
Outcomes of Patients With Multiple Myeloma With deletion 1p Following Autologous Stem Cell TransplantCurtis Marcoux, Denái R Milton, Mark R Tanner, et al.
Blood Cancer Journal|November 1, 2024
Optimal infused CD34<sup>+</sup> cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantationOren Pasvolsky, Curtis Marcoux, Denái R Milton, et al.
The American Journal of Surgical Pathology|February 13, 2016
Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 CasesMariko Yabe, L Jeffrey Medeiros, Guilin Tang, et al.
Blood Cancer Journal|May 3, 2023
Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patientsOren Pasvolsky, Denái R Milton, Mikael Rauf, et al.
Blood|December 16, 2021
Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemiaMahmoud R Gaballa, Pinaki Banerjee, Denái R Milton, et al.
Bone Marrow Transplantation|December 5, 2025
Results of delayed or salvage autologous hematopoietic stem cell transplantation for multiple myelomaOren Pasvolsky, Curtis Marcoux, Denái R Milton, et al.
Haematologica|June 4, 2026
Long-term follow-up: blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemiaJennifer Miatech, Denái R Milton, Mahmoud R Gaballa, et al.
Bone Marrow Transplantation|December 20, 2016
Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patientsB S Andersson, P F Thall, B C Valdez, et al.
Transplantation and Cellular Therapy|January 2, 2025
Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell TransplantationOren Pasvolsky, Curtis Marcoux, Zhongya Wang, et al.
Pageof 19

Showing results (151-160 of 182) with videos related to

Sort By:
Pageof 19
Transplantation and Cellular Therapy|May 18, 2025
Outcomes of Multiple Myeloma Patients With Prior Solid Tumors Undergoing Autologous TransplantationOren Pasvolsky, Curtis Marcoux, Denái R Milton, et al.
Transplantation and Cellular Therapy|August 2, 2025
Outcomes of Patients With Multiple Myeloma With deletion 1p Following Autologous Stem Cell TransplantCurtis Marcoux, Denái R Milton, Mark R Tanner, et al.
Blood Cancer Journal|November 1, 2024
Optimal infused CD34<sup>+</sup> cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantationOren Pasvolsky, Curtis Marcoux, Denái R Milton, et al.
The American Journal of Surgical Pathology|February 13, 2016
Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 CasesMariko Yabe, L Jeffrey Medeiros, Guilin Tang, et al.
Blood Cancer Journal|May 3, 2023
Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patientsOren Pasvolsky, Denái R Milton, Mikael Rauf, et al.
Blood|December 16, 2021
Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemiaMahmoud R Gaballa, Pinaki Banerjee, Denái R Milton, et al.
Bone Marrow Transplantation|December 5, 2025
Results of delayed or salvage autologous hematopoietic stem cell transplantation for multiple myelomaOren Pasvolsky, Curtis Marcoux, Denái R Milton, et al.
Haematologica|June 4, 2026
Long-term follow-up: blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemiaJennifer Miatech, Denái R Milton, Mahmoud R Gaballa, et al.
Bone Marrow Transplantation|December 20, 2016
Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patientsB S Andersson, P F Thall, B C Valdez, et al.
Transplantation and Cellular Therapy|January 2, 2025
Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell TransplantationOren Pasvolsky, Curtis Marcoux, Zhongya Wang, et al.
Pageof 19